TABLE 1

Summary of predicted hepatic clearance of aldehyde oxidase substrates in cryopreserved human hepatocytes compared with reported human pharmacokinetic properties

Hepatic clearance estimates (ml · min⁻¹ · kg⁻¹) were calculated as described under Materials and Methods. Data are presented as mean (S.D.) from n = 4 replicates.

Substrate	Predicted Hepatic Clearance^{^a}	Predicted Hepatic Clearance^{^b}	E_h^{^c}	Predicted Oral Bioavailability^{^d}	Human Total Clearance	Human Oral Bioavailability	Reference
	ml · min⁻¹ · kg⁻¹				ml · min⁻¹ · kg⁻¹	%F
BIBX1382	17.6 (0.2)	18.2 (0.2)	85–88	12–15	25–55	2–12	Dittrich et al., 2002
Carbazeran	17.8 (0.1)	17.3 (0.6)	84–86	14–16	38	<5	Kaye et al., 1984
O⁶-Benzylguanine	11.2 (0.2)	12.8 (0.2)	54–62		15.6		Dolan et al., 1998
Zaleplon	<4.3	<4.3	<21	>79	15.7	30	Rosen et al., 1999
XK-469	<4.3	<4.3	<21		<1		Alousi et al., 2007

↵a Celsis/In Vitro Technologies (lot OOO).
↵b Life Technologies, Inc. (lot HuE104).
↵c Calculated using eq. 3 using range of hepatic clearance values observed in cryopreserved hepatocytes.
↵d Calculated using eq. 5.